Star Equity Holdings, Inc. (STRR)
USD 2.36
(-2.88%)
USD 2.36
(-2.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.34 Million USD | -31.82% |
| 2022 | -3.1 Million USD | 65.82% |
| 2021 | -9.08 Million USD | -34.13% |
| 2020 | -6.77 Million USD | -388.25% |
| 2019 | -1.38 Million USD | 69.48% |
| 2018 | -4.54 Million USD | 24.49% |
| 2017 | -6.01 Million USD | -295.11% |
| 2016 | 3.08 Million USD | 11.21% |
| 2015 | 2.77 Million USD | 10.17% |
| 2014 | 2.51 Million USD | 1372.51% |
| 2013 | 171 Thousand USD | 103.35% |
| 2012 | -5.09 Million USD | -45.24% |
| 2011 | -3.51 Million USD | 46.74% |
| 2010 | -6.59 Million USD | -11462.07% |
| 2009 | 58 Thousand USD | 100.76% |
| 2008 | -7.62 Million USD | -168.36% |
| 2007 | -2.84 Million USD | 65.45% |
| 2006 | -8.22 Million USD | 25.26% |
| 2005 | -11 Million USD | -1990.55% |
| 2004 | 582 Thousand USD | 304.81% |
| 2003 | -284.16 Thousand USD | 97.38% |
| 2002 | -10.84 Million USD | 35.99% |
| 2001 | -16.94 Million USD | -30.97% |
| 2000 | -12.93 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.96 Million USD | -574.09% |
| 2024 Q2 | -3.77 Million USD | -5.29% |
| 2023 Q4 | -440 Thousand USD | 73.51% |
| 2023 Q3 | -1.66 Million USD | 18.42% |
| 2023 FY | -4.09 Million USD | -31.82% |
| 2023 Q1 | 730 Thousand USD | -65.87% |
| 2023 Q2 | -2.03 Million USD | -378.9% |
| 2022 FY | -3.1 Million USD | 65.82% |
| 2022 Q1 | -2.55 Million USD | 29.67% |
| 2022 Q2 | -1.2 Million USD | 52.88% |
| 2022 Q3 | -1.49 Million USD | -23.84% |
| 2022 Q4 | 2.13 Million USD | 243.46% |
| 2021 Q3 | -1.88 Million USD | 58.23% |
| 2021 Q2 | -4.51 Million USD | -187.44% |
| 2021 FY | -9.08 Million USD | -34.13% |
| 2021 Q1 | -1.56 Million USD | 38.4% |
| 2021 Q4 | -3.63 Million USD | -92.83% |
| 2020 FY | -6.77 Million USD | -388.25% |
| 2020 Q2 | -1.52 Million USD | 41.4% |
| 2020 Q3 | -1.53 Million USD | -0.46% |
| 2020 Q4 | -2.54 Million USD | -66.14% |
| 2020 Q1 | -2.6 Million USD | -2452.94% |
| 2019 FY | -1.38 Million USD | 69.48% |
| 2019 Q4 | -102 Thousand USD | 91.56% |
| 2019 Q1 | -1.13 Million USD | 18.81% |
| 2019 Q2 | -1.14 Million USD | -0.97% |
| 2019 Q3 | -1.2 Million USD | -5.5% |
| 2018 Q4 | -1.39 Million USD | -8.37% |
| 2018 Q3 | -1.29 Million USD | -420.16% |
| 2018 FY | -4.54 Million USD | 24.49% |
| 2018 Q1 | -1.6 Million USD | -77.79% |
| 2018 Q2 | -248 Thousand USD | 84.59% |
| 2017 Q1 | -975 Thousand USD | -166.01% |
| 2017 FY | -6.01 Million USD | -295.11% |
| 2017 Q4 | -905 Thousand USD | 62.1% |
| 2017 Q3 | -2.38 Million USD | -36.38% |
| 2017 Q2 | -1.75 Million USD | -79.59% |
| 2016 Q1 | -553 Thousand USD | -211.04% |
| 2016 Q4 | 1.47 Million USD | 114.37% |
| 2016 Q3 | 689 Thousand USD | -53.19% |
| 2016 FY | 3.08 Million USD | 11.21% |
| 2016 Q2 | 1.47 Million USD | 366.18% |
| 2015 Q2 | 1.16 Million USD | 604.85% |
| 2015 FY | 2.77 Million USD | 10.17% |
| 2015 Q4 | 498 Thousand USD | -47.47% |
| 2015 Q1 | 165 Thousand USD | -79.78% |
| 2015 Q3 | 948 Thousand USD | -18.49% |
| 2014 Q1 | -155 Thousand USD | -119.87% |
| 2014 Q2 | 825 Thousand USD | 632.26% |
| 2014 FY | 2.51 Million USD | 1372.51% |
| 2014 Q4 | 816 Thousand USD | -20.93% |
| 2014 Q3 | 1.03 Million USD | 25.09% |
| 2013 Q2 | -632 Thousand USD | 73.77% |
| 2013 FY | 171 Thousand USD | 103.35% |
| 2013 Q4 | 780 Thousand USD | -67.93% |
| 2013 Q3 | 2.43 Million USD | 484.81% |
| 2013 Q1 | -2.4 Million USD | -30.71% |
| 2012 FY | -5.09 Million USD | -45.24% |
| 2012 Q3 | -1.06 Million USD | -17.77% |
| 2012 Q2 | -906 Thousand USD | 29.33% |
| 2012 Q1 | -1.28 Million USD | 49.27% |
| 2012 Q4 | -1.84 Million USD | -72.73% |
| 2011 Q1 | -647 Thousand USD | -2.05% |
| 2011 FY | -3.51 Million USD | 46.74% |
| 2011 Q4 | -2.52 Million USD | -4759.62% |
| 2011 Q3 | -52 Thousand USD | 81.82% |
| 2011 Q2 | -286 Thousand USD | 55.8% |
| 2010 FY | -6.59 Million USD | -11462.07% |
| 2010 Q1 | -1.37 Million USD | -4848.28% |
| 2010 Q4 | -634 Thousand USD | 56.84% |
| 2010 Q3 | -1.46 Million USD | 52.78% |
| 2010 Q2 | -3.11 Million USD | -125.93% |
| 2009 FY | 58 Thousand USD | 100.76% |
| 2009 Q2 | 638 Thousand USD | 771.58% |
| 2009 Q3 | -514 Thousand USD | -180.56% |
| 2009 Q1 | -95 Thousand USD | 97.31% |
| 2009 Q4 | 29 Thousand USD | 105.64% |
| 2008 Q1 | -1.69 Million USD | -29.4% |
| 2008 Q2 | -1.41 Million USD | 16.77% |
| 2008 Q3 | -981 Thousand USD | 30.62% |
| 2008 Q4 | -3.52 Million USD | -259.73% |
| 2008 FY | -7.62 Million USD | -168.36% |
| 2007 Q4 | -1.31 Million USD | -35.08% |
| 2007 Q1 | -416 Thousand USD | 31.01% |
| 2007 Q2 | -140 Thousand USD | 66.35% |
| 2007 FY | -2.84 Million USD | 65.45% |
| 2007 Q3 | -972 Thousand USD | -594.29% |
| 2006 Q2 | -1.63 Million USD | 50.42% |
| 2006 Q3 | -2.68 Million USD | -64.12% |
| 2006 FY | -8.22 Million USD | 25.26% |
| 2006 Q1 | -3.3 Million USD | -2.33% |
| 2006 Q4 | -603 Thousand USD | 77.54% |
| 2005 Q3 | -3.21 Million USD | 3.92% |
| 2005 Q4 | -3.22 Million USD | -0.44% |
| 2005 FY | -11 Million USD | -1990.55% |
| 2005 Q1 | -1.22 Million USD | -601.93% |
| 2005 Q2 | -3.34 Million USD | -172.82% |
| 2004 Q4 | -174.52 Thousand USD | -154.63% |
| 2004 Q2 | 358.01 Thousand USD | 352.8% |
| 2004 FY | 582 Thousand USD | 304.81% |
| 2004 Q3 | 319.43 Thousand USD | -10.78% |
| 2004 Q1 | 79.06 Thousand USD | 0.0% |
| 2003 Q2 | -374.96 Thousand USD | 37.72% |
| 2003 Q1 | -602.03 Thousand USD | 0.0% |
| 2003 FY | -284.16 Thousand USD | 97.38% |
| 2002 FY | -10.84 Million USD | 35.99% |
| 2001 FY | -16.94 Million USD | -30.97% |
| 2000 FY | -12.93 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -215.24 Million USD | 97.981% |
| Prenetics Global Limited | -52.51 Million USD | 91.724% |
| CareDx, Inc | -101.9 Million USD | 95.735% |
| Exact Sciences Corporation | -215.01 Million USD | 97.979% |
| Exagen Inc. | -22.83 Million USD | 80.969% |
| Inotiv, Inc. | -81.46 Million USD | 94.665% |
| Guardant Health, Inc. | -564.72 Million USD | 99.23% |
| Biodesix, Inc. | -41.34 Million USD | 89.488% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -67.567% |
| Precipio, Inc. | -7.62 Million USD | 42.966% |
| iSpecimen Inc. | -11.16 Million USD | 61.09% |
| Natera, Inc. | -446.24 Million USD | 99.026% |
| Aspira Women's Health Inc. | -18.85 Million USD | 76.947% |
| Standard BioTools Inc. | -76.6 Million USD | 94.326% |
| 23andMe Holding Co. | -321.35 Million USD | 98.648% |
| Castle Biosciences, Inc. | -67.97 Million USD | 93.607% |
| Personalis, Inc. | -109.93 Million USD | 96.047% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 95.536% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 60.322% |
| OpGen, Inc. | -15.68 Million USD | 72.298% |
| T2 Biosystems, Inc. | -49.66 Million USD | 91.249% |
| Myriad Genetics, Inc. | -123.7 Million USD | 96.487% |
| ICON Public Limited Company | 956.15 Million USD | 100.455% |
| NeoGenomics, Inc. | -107.73 Million USD | 95.966% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -0.0% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.396% |
| RadNet, Inc. | 98.69 Million USD | 104.403% |
| MDxHealth SA | -27.32 Million USD | 84.096% |
| Psychemedics Corporation | -2.92 Million USD | -48.785% |
| Illumina, Inc. | -1.06 Billion USD | 99.593% |
| Check-Cap Ltd. | -19.28 Million USD | 77.467% |
| Twist Bioscience Corporation | -220.83 Million USD | 98.032% |
| DarioHealth Corp. | -56.18 Million USD | 92.265% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 94.022% |
| Sera Prognostics, Inc. | -39.82 Million USD | 89.086% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 58.691% |
| OPKO Health, Inc. | -157.02 Million USD | 97.232% |
| Medpace Holdings, Inc. | 336.82 Million USD | 101.29% |
| Neogen Corporation | 58.66 Million USD | 107.408% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 57.737% |
| Prenetics Global Limited | -52.51 Million USD | 91.724% |
| Mainz Biomed B.V. | -26.64 Million USD | 83.689% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 45.493% |
| Trinity Biotech plc | -27.04 Million USD | 83.93% |
| Neuronetics, Inc. | -30.55 Million USD | 85.776% |
| Sotera Health Company | 276.69 Million USD | 101.571% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 45.493% |